Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15256356 | 0.88 | PIK3CG (0.48) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL2304665 | 0.86 | MAPT (0.52) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL2303330 | 0.85 | PIK3CG (0.50) | MAPTKMT2AMEN1KDM4ELMNA | |
| SCHEMBL2307067 | 0.85 | PIK3CG (0.47) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL15192988 | 0.84 | MAPT (0.46) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL15193807 | 0.83 | NPC1 (0.45) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL15193833 | 0.83 | NPC1 (0.45) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL7699357 | 0.83 | KMT2A (0.62) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL15193251 | 0.81 | NPC1 (0.43) | MAPTKMT2AMEN1TP53KDM4E | |
| SCHEMBL2301255 | 0.81 | MAPT (0.45) | MAPTKMT2AMEN1TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | claimed |
| JP-2009506015-A | — | — | 2009-02-12 | — | — | JP | claimed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | claimed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| EP-2351745-A1 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono S.A. (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351745-A1 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono S.A. (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | MAPT 2973/4885KMT2A 3815/4885MEN1 1772/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | MAPT 3146/4885KMT2A 4603/4885MEN1 3412/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | MAPT 3146/4885KMT2A 4603/4885MEN1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.